Viktor Gruenwald

TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.

TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.

TL;DR: A comparative analysis of the two studies is performed to identify potential factors in the control arm that can impact clinical trial bio-statistical outcomes and which may have implications for future immunotherapy clinical trial designs.

TL;DR: In this article , the authors presented an overview of the prospective FAPI PET registry study across a 3-y period, with head-to-head comparison of tumor uptake in 68Ga-FAPI and 18F-FDG PET, as well as FAP immunohistochemistry.

TL;DR: This collection contains 10 reports published in Frontiers in Oncology between August 2020 and March 2022 broadly focused on the immunobiology of renal cell carcinoma (RCC), the impact of immunotherapy in the setting of RCC, and the identification of biomarkers that are prognostic of R CC patient outcomes and response to immunotherapy.